EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte Studie

Preclinical and phase I randomized study of a potent inhalable nanobody targeting TSLP for the treatment of airway inflammation

Min Zhu, Linlin Ma, Junwei Gai, Guanghui Li, Jing Huang, Xiaofei Li, Peng Qiao, Juan Su, Siran Pei, Yakun Wan

Journal of Allergy and Clinical Immunology · 2025

DOI: 10.1016/j.jaci.2025.06.024 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025. Verfasst von Min Zhu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Novamab Biopharmaceuticals Co, Ltd, Shanghai, China. Hauptthemen laut MEDLINE: Cytokines, Single-Domain Antibodies, Inflammation, Asthma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, Shanghai Science and Technology Development Foundation, Science and Technology Innovation Plan Of Shanghai Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytokinesSingle-Domain AntibodiesInflammationAsthmaAnimalsHumansMiceAdministration, InhalationFemaleThymic Stromal LymphopoietinMaleDouble-Blind MethodAdultMice, Inbred BALB C

Stichwörter der Autor:innen

TSLPairway inflammationinhalablenanobody

Substanzen

CytokinesSingle-Domain AntibodiesThymic Stromal LymphopoietinTSLP protein, human

Autor:innen und Institutionen

  • Shanghai Novamab Biopharmaceuticals Co, Ltd, Shanghai, China.
  • School of Medical Technology, Shanghai University of Medicine and Health Sciences, Shanghai, China.
  • Shanghai Novamab Biopharmaceuticals Co, Ltd, Shanghai, China. Electronic address: ykwan@novamab.com.

Förderung

  • Science and Technology Commission of Shanghai Municipality
  • Shanghai Science and Technology Development Foundation
  • Science and Technology Innovation Plan Of Shanghai Science and Technology Commission

Zitieren

APA

Zhu, M., Ma, L., Gai, J., Li, G., Huang, J., Li, X., Qiao, P., Su, J., Pei, S., & Wan, Y. (2025). Preclinical and phase I randomized study of a potent inhalable nanobody targeting TSLP for the treatment of airway inflammation. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2025.06.024

Vancouver

Zhu M, Ma L, Gai J, Li G, Huang J, Li X, et al. Preclinical and phase I randomized study of a potent inhalable nanobody targeting TSLP for the treatment of airway inflammation. Journal of Allergy and Clinical Immunology. 2025. doi:10.1016/j.jaci.2025.06.024

BibTeX
@article{Zhu2025,
  author = {Zhu, Min and Ma, Linlin and Gai, Junwei and Li, Guanghui and Huang, Jing and Li, Xiaofei and Qiao, Peng and Su, Juan and Pei, Siran and Wan, Yakun},
  title = {Preclinical and phase I randomized study of a potent inhalable nanobody targeting TSLP for the treatment of airway inflammation},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2025},
  doi = {10.1016/j.jaci.2025.06.024}
}
Kostenlos starten →